The better you follow the directions, the less chance you have of getting pregnant.Based on the results from the clinical study, about 3 out of 100 women may get pregnant during the first year they use Tri-Lo-Marzia.The following chart shows the chance of getting pregnant for women who use different methods of birth control. Tri-Lo-Marzia are available in a wallet (NDC 63187-754-28) containing 28 tablets packed in a Each wallet (28 tablets) contains in the following order: • 7 white to off white, round, film-coated tablets debossed with 'LU' on one side and "E21" on the other side contains 0.18 mg norgestimate and 0.025 mg ethinyl estradiol • o  Have deep vein thrombosis or pulmonary embolism, now or in the past   o  Have inherited or acquired hypercoagulopathies    o  Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)    o  Have diabetes mellitus with vascular disease    o  Have headaches with focal neurological symptoms or migraine headaches with aura          o Women over age 35 with any migraine headaches Do not use Tri-Lo-Marzia in women with liver disease, such as acute viral hepatitis or severe (decompensated) cirrhosis of liver Tri-Lo-Marzia is contraindicated in women with benign and malignant liver tumors Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (>8 years) COC users. 2 Aluminium Lake, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone and titanium dioxide.Blue pills: anhydrous lactose, croscarmellose sodium, FD&C Blue No. 2 Aluminium Lake, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone and titanium dioxide.Green pills: croscarmellose sodium, FD&C Blue No. NGM is rapidly and completely metabolized by first pass (intestinal and/or hepatic) mechanisms to norelgestromin (NGMN) and norgestrel (NG), which are the major active metabolites of NGM.Mean pharmacokinetic parameters for NGMN, NG and EE during three cycles of administration of Tri-Lo-Marzia are summarized in Table 3.Peak serum concentrations of NGMN and EE were generally reached by 2 hours after administration of Tri-Lo-Marzia. Remove pill "1" by pushing down on the pill.What should I do if I miss any Tri-Lo-Marzia pills?If you miss 1 pill in Weeks 1, 2, or 3, follow these steps:If you miss 2 pills in Week 1 or Week 2 of your pack, follow these steps:If you miss 2 pills in a row in Week 3, or you miss 3 or more pills in a row during Weeks 1, 2, or 3 of the pack, follow these steps:If you have any questions or are unsure about the information in this leaflet, call your healthcare provider. However, the risk of liver cancers in COC users is less than one case per million users.An increase in blood pressure has been reported in women taking COCs, and this increase is more likely in older women with extended duration of use. Subsequent hepatic metabolism of NGMN occurs and metabolites include NG, which is also active and various hydroxylated and conjugated metabolites. Subjects were followed for up to 13 28-day cycles.The most common adverse reactions reported by at least 2% of the 1,723 women using the 28-day regimen were the following in order of decreasing incidence: headache/migraine (30.5%), nausea/vomiting (16.3%); breast issues (including tenderness, pain, enlargement, swelling, discharge, discomfort, cyst, and nipple pain) (10.3%), abdominal pain (9.2%), menstrual disorders (including dysmenorrhea, menstrual discomfort, menstrual disorder) (9.2%), mood disorders (including depression, mood altered, mood swings and depressed mood) (7.6%); acne (5.1%), vulvovaginal infection (3.5%), abdominal distension (2.8%), weight increased (2.4%), fatigue (2.1%).In the clinical trial of Tri-Lo-Marzia 4% of subjects discontinued the trial due to an adverse reaction. If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different contraceptive product.In the clinical trial of Tri-Lo-Marzia, the frequency and duration of unscheduled bleeding and/or spotting was assessed in 1,673 women (11,015 evaluable cycles). Our team at […]